NCT05283837View on ClinicalTrials.gov

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

PHASE3CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

September 6, 2023

Study Completion Date

September 6, 2023

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

Pertuzumab (ZRC-3277)

Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.

BIOLOGICAL

Pertuzumab (Perjeta®)

Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.

Trial Locations (1)

Unknown

Unique Hospital-Multispeciality & Resesarch Institute, Sūrat

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY